Passage BIO, Inc. Files Q1 2025 10-Q

Ticker: PASG · Form: 10-Q · Filed: May 13, 2025 · CIK: 1787297

Sentiment: neutral

Topics: 10-Q, biotechnology, financials

TL;DR

Passage BIO's Q1 2025 10-Q is in. Check financials.

AI Summary

Passage BIO, Inc. filed its 10-Q for the period ending March 31, 2025. The company, incorporated in Delaware, operates in the biological products sector. Its principal executive offices are located in Philadelphia, PA. The filing covers the first quarter of 2025.

Why It Matters

This filing provides investors with an update on Passage BIO's financial performance and operational status for the first quarter of 2025, crucial for understanding the company's trajectory in the biotechnology sector.

Risk Assessment

Risk Level: medium — Biotechnology companies often carry higher risk due to the nature of drug development, regulatory hurdles, and market volatility.

Key Numbers

Key Players & Entities

FAQ

What is the primary business of Passage BIO, Inc.?

Passage BIO, Inc. is involved in the biological products sector, specifically noted as 'BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)' with SIC code 2836.

When was this 10-Q filing submitted?

This 10-Q filing was submitted on May 13, 2025.

What is the fiscal year end for Passage BIO, Inc.?

The fiscal year end for Passage BIO, Inc. is December 31.

Where are Passage BIO, Inc.'s principal executive offices located?

Passage BIO, Inc.'s principal executive offices are located at One Commerce Square, 2005 Market Street, 39th Floor, Philadelphia, PA 19103.

What is the SEC file number for Passage BIO, Inc.?

The SEC file number for Passage BIO, Inc. is 001-39231.

Filing Details

This Form 10-Q (Form 10-Q) was filed with the SEC on May 13, 2025 regarding Passage BIO, Inc. (PASG).

View full filing on EDGAR

View Full Filing

View this 10-Q filing on SEC EDGAR

View on Read The Filing